Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus

J Diabetes Complications. 2023 Dec;37(12):108630. doi: 10.1016/j.jdiacomp.2023.108630. Epub 2023 Oct 23.
No abstract available

Keywords: Cardiovscular; Empagliflozin; Outcome; Renal; SGLT-2 inhibitor; Type 2 diabetes.

Publication types

  • Editorial

MeSH terms

  • Benzhydryl Compounds* / therapeutic use
  • Cardiovascular Diseases / prevention & control
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetic Cardiomyopathies / prevention & control
  • Diabetic Nephropathies / drug therapy
  • Glucosides* / pharmacology
  • Glucosides* / therapeutic use
  • Humans
  • Hypoglycemic Agents* / therapeutic use
  • Kidney / drug effects
  • Kidney / physiopathology
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • empagliflozin
  • Glucosides
  • Benzhydryl Compounds
  • Sodium-Glucose Transporter 2 Inhibitors
  • Hypoglycemic Agents